Mektovi (binimetinib) is an oral kinase inhibitor that may be used in combination with encorafenib
for the treatment of adults with:
* unresectable or metastatic melanoma with a confirmed BRAF V600E or V600K mutation
* metastatic non-small cell lung cancer (NSCLC) with a confirmed BRAF V600E mutation.
Mektovi is a reversible inhibitor of two proteins, mitogen-activated extracellular signal-regulated
kinase 1 (MEK1) and MEK2. These are upstream regulators of the extracellular signal-related
kinase (ERK) pathway and blocking them results in an inhibition of extracellular signal-related
kinase (ERK) phosphorylation as well as the viability and MEK-dependent phosphorylation of
BRAF-mutations
For more information
Email : sales@lexionpham
Website : www.lexionpham.com